Moberg Pharma
Moberg Pharma AB is a Swedish pharmaceutical company focused on developing and commercializing topical dermatological treatments. The company specializes in developing MOB-015, a proprietary topical formulation of terbinafine for the treatment of onychomycosis, or nail fungus. Revenue is primarily generated through milestone payments, upfront licensing agreements, and commercial distribution contracts with international pharmaceutical partners. Core end markets encompass prescription patients, dermatology clinics, and retail pharmacy chains across Europe, North America, and Asia. Moberg Pharma holds a specialized position in the European specialty pharmaceutical industry through its proprietary topical drug delivery technologies. The company is headquartered in Stockholm, Sweden, and its ordinary shares trade on the Nasdaq Stockholm exchange.
2 of the funds FundTelligence covers report a position in Moberg Pharma.
- Legal name
- Moberg Pharma AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Moberg Pharma
- Storebrand Sverige Småbolag Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)